Relating statin therapy to C-reactive protein levels

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 9, 2005, Pages 1597-1600

  Doggrell, Shiela A ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

Atorvastatin; Cardiovascular risk; Clinical trials; JUPITER; Pravastatin; PROVE IT; REVERSAL

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN;

ACUTE DISEASE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG USE; ECHOGRAPHY; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INFLAMMATION; LONG TERM CARE; MORTALITY; PREDICTION; PRIMARY PREVENTION; RECURRENT DISEASE; RISK ASSESSMENT; SEX DIFFERENCE; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 23644457662     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.9.1597     Document Type: Article

References (18)

1. VENUGOPAL SK, DEVERAJ S, JIALAL I: Effect of C-reactive proteins on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr. Opin. Nephrol. Hypertens. (2005) 14:33-37.
2. RIDKER PM, RIFAL N, ROSE L, BURING JE, COOK NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. (2002) 347:1557-1565.
3. LIAO JK, LAUFS U. Pleiotropic effects of statins. Ann. Rev. Pharmacol. Toxicol. (2005) 45:89-115.
4. NISSEN SE, TUZCU EM, SHOENHAGEN P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomised controlled trial. JAMA (2004) 291:1071-1080.
5. NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N. Engl. J. Med. (2005) 352:29-38.
6. CANNON CP, BRAUNWALD E, MCCABE CH et al.: Intensive versus moderate lipid lowering statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350:1495-1504.
7. RIDKER PM, CANNON CR, MORROW D et al.: C-Reactive Protein levels and outcomes after statin therapy. N. Engl. J. Med. (2005) 352:20-28.
8. RIDKER RM, MORROW DA, ROSE LM et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/l: an analysis of the PROVE-IT TIMI-22 trial J. Am. Coll. Cardiol. (2005) 45(10):1644-1648.
9. ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM, PRINCE INVESTIGATORS: Effect of statin therapy on C-reaccive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 286:64-70.
10. KOENIG W, LÖWEL H, BAUMERT J, MEISINGER C: C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation (2004) 109:1349-1353.
11. RIKER PM, BURING JE, COOK NR, RIFAI N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation (2003) 107:391-397.
12. LAAKSONEN DE, NISKANEN L, NYYSSONEN K et al.: C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia (2004) 47:1403-1410.
13. RUTTER MK, MEIGS JB, SULLIVAN LM, D'AGOSTINO RB Sr, WILSON PW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation (2004) 110:380-385.
14. NAKANISHI N, SHIRAISHI T, WADA M: C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. Circ. J. (2005) 69:386-391.
15. BO S, GENTILE L, CICCONE G et al.: The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab. Res. Rev. (2005) 10:[Epub ahead of print].
16. WOLOSHIN S, SCHWARTZ LM: Distribution of C-reactive protein values in the United States. N. Engl. J. Med. (2005) 325:1611-1613.
17. MILANI RV, LAVIE QJ, MEHRA MR: Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J. Am. Coll. Cardiol. (2004) 43:1056-1061.
18. RIKER PM: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation (2003) 108:2292-2297.